2′-C-methyl-ribofuranosyl cytidine prodrugs,...

Details 2′-C-methyl-ribofuranosyl cytidine prodrugs,... 2′-C-methyl-ribofuranosyl cytidine prodrugs,...

2007-05-22

2011-11-15

Crane, Lawrence E (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S028500, C536S028510

Reexamination Certificate

active

08058260

ABSTRACT:
The present disclosure provides 2′-C-methyl-ribofuranosyl cytidine prodrugs, methods of making 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions of 2′-C-methyl-ribofuranosyl cytidine prodrugs, and methods of using 2′-C-methyl-ribofuranosyl cytidine prodrugs and pharmaceutical compositions thereof to treat viral diseases such as hepatitis C.

REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 6812219 (2004-11-01), LaColla et al.
patent: 6914054 (2005-07-01), Sommadossi et al.
patent: 7101861 (2006-09-01), Sommadossi et al.
patent: 7105493 (2006-09-01), Sommadossi et al.
patent: 7148206 (2006-12-01), Sommadossi et al.
patent: 7163929 (2007-01-01), Sommadossi et al.
patent: 7192936 (2007-03-01), LaColla et al.
patent: 7429572 (2008-09-01), Clark
patent: 7582618 (2009-09-01), Sommadossi et al.
patent: 7632821 (2009-12-01), Butora et al.
patent: 7645745 (2010-01-01), Sarma
patent: 2004/0077587 (2004-04-01), Sommadossi et al.
patent: 2004/0142857 (2004-07-01), Gallop et al.
patent: WO 01/20331 (2001-03-01), None
patent: WO 2004/002999 (2004-01-01), None
patent: WO 2004/003000 (2004-01-01), None
Alderman, A review of cellulose ethers in hydrophilic matrices for oral controlled release dosage forms,Int. J. Pharm. Tech.&Prod. Mfg., 1984, 5(3), 1-9.
Balimane et al., Involvement of multiple transporters in the oral absorption of nucleoside analogues,Adv. Drug Delivery Rev.1999, 39, 183-209.
Bamba et al., Release mechanisms in gelforming sustained release preparations,Int. J. Pharm., 1979, 2, 307-315.
Boyer, et al., Pathogenesis, diagnosis and management of hepatitis C,J. Hepatol.2000, 32, 98-112.
Clark et al., Design, synthesis and antiviral activity of 2′-deoxy-2′-fluor-2′-c′-methylcytidine, a potent inhibitor of hepatitis C virus replication,J. Med. Chem.2005, 48, 5504-5508.
Di Bisceglie et al., The unmet challenges, Scientific American Oct. 1999, 80-85.
During, et al., Controlled release of dopamine from a polymeric brain implant: in vivo characterization, 1989,Ann. Neurol.25, 351.
Goodson, in “Medical Applications of Controlled Release,”supra, vol. 2, pp. 1.15-138 (1984).
Howard et al. Intracerebral drug delivery in rats with lesion-induced memory deficits,J. Neurosurg.71,105-112.
Langer, R. , (1983). Chemical and physical structure of polymers as carriers for controlled release of bioactive agents: a review. JMS Rev Macromol Chem. Phys. C23(1), 61-126.
Langer, 1990, New methods of drug deliveryScience249,1527-1533.
Leibach, et al., Peptide transporter in the intestine and kidney,Annu. Rev. Nutr.1996, 16, 99-119.
Levy, et al., Inhibition of calcification of bioprosthetic heart valves by local controlled—release diphosphonateScience228, 190-192.
Pierra et al.,Nucleosides, Nucleotides2005, 24, 767-770.
Pierra et al.,J. Med. Chem.2006, 49, 6614-6620.
Rice, C. M., Flaviviridae: The viruses and their replication. In:Fields Virology, Editors: Fields, B. N., Knipe, D. M., and Howley, P. M., Lippincott-Raven Publishers, Philadelphia, Pa., Chapter 30, 931-959, 1996.
Saudek et al., A preliminary trial of the programmable implantable medication system for insulin delivery ,1989,N. Engl. J Med.321, 574-579.
Sefton, 1987, Implantable Pumps,CRC Crit Ref Biomed Eng.14, 201-240.
Verma et al., Osmotically Controlled Oral Drug Delivery,Drug Dev. Ind. Pharm., 2000, 26, 695-708.
Kolor, Patient Education and Treatment Strategies Implemented at a Pharmacist-Managed Hepatitis C Virus Clinic,Pharmacother. (2005), 25(9): 1230-1241.
Moreno-Otero, et al., Is interferon-beta an alternative treatment for chronic hepatitis C?,W. J. Gastroenterol.(2006), 12(17): 2730-2736.
Moriyama, et al., Treatment of interferon-α for chronic hepatitis C,Expert Opin. Pharmacother.(2006), 7(9): 1163-1179.

Affiliated with

Also associated with

Rating

2′-C-methyl-ribofuranosyl cytidine prodrugs,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 2′-C-methyl-ribofuranosyl cytidine prodrugs,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2′-C-methyl-ribofuranosyl cytidine prodrugs,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4295859